Innocan Pharma Corp
F:IP40
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Innocan Pharma Corp
F:IP40
|
IL |
|
Vetoquinol SA
LSE:0O1O
|
FR |
|
Banc of California Inc
NYSE:BANC
|
US |
|
Wacker Chemie AG
F:WCH
|
DE |
|
G
|
GFT Technologies SE
SWB:GFT
|
DE |
|
BlackRock Inc
MIL:1BLK
|
US |
|
W
|
Weichai Power Co Ltd
OTC:WEICF
|
CN |
|
S
|
Stanley Black & Decker Inc
F:SWF
|
US |
|
Casio Computer Co Ltd
F:CAC1
|
JP |
|
S
|
Spotify Technology SA
XETRA:639
|
LU |
|
E
|
EssilorLuxottica SA
OTC:ESLOF
|
FR |
|
Donear Industries Ltd
NSE:DONEAR
|
IN |
|
A
|
Asia Precision PCL
SET:APCS
|
TH |
|
E
|
Evolus Inc
SWB:EVL
|
US |
|
Swedbank AB
LSE:0H6T
|
SE |
|
Peak Rare Earths Ltd
ASX:PEK
|
AU |
|
D
|
Darktrace PLC
OTC:DRKTY
|
UK |
Innocan Pharma Corp
Innocan Pharma Corp develops drug products based on cannabinoids, the active compounds from cannabis plants, with a focus on long-acting therapies for pain relief and other medical uses. The company is trying to turn cannabis-derived ingredients into regulated pharmaceutical products rather than consumer hemp or recreational items. Its main customers are the healthcare and pharmaceutical markets, including patients, doctors, and eventually distributors or partners that can commercialize approved products. Innocan makes money through product development, licensing, and collaboration with third parties, with its value tied to moving cannabinoid science through testing, regulatory review, and into sellable medicines. What makes the business different is that it sits between the cannabis industry and drug development. Instead of selling flowers, oils, or wellness products directly to consumers, Innocan is working on injectable and topical formulations that could become prescription-grade treatments, which puts it in a more research-driven and regulated part of the market.
Innocan Pharma Corp develops drug products based on cannabinoids, the active compounds from cannabis plants, with a focus on long-acting therapies for pain relief and other medical uses. The company is trying to turn cannabis-derived ingredients into regulated pharmaceutical products rather than consumer hemp or recreational items.
Its main customers are the healthcare and pharmaceutical markets, including patients, doctors, and eventually distributors or partners that can commercialize approved products. Innocan makes money through product development, licensing, and collaboration with third parties, with its value tied to moving cannabinoid science through testing, regulatory review, and into sellable medicines.
What makes the business different is that it sits between the cannabis industry and drug development. Instead of selling flowers, oils, or wellness products directly to consumers, Innocan is working on injectable and topical formulations that could become prescription-grade treatments, which puts it in a more research-driven and regulated part of the market.
